Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
CJC 1295 (without DAC)
CAS: 446036-97-1
Estudiado para la liberación pulsátil de GH imitando el ritmo natural
CJC 1295 (without DAC) is a research peptide in the growth hormone / gh secretagogues category. Mod GRF 1-29 is a modified 29-amino acid fragment of GHRH with four amino acid substitutions that prevent enzymatic degradation: D-Ala2 prevents DPP-IV cleavage, Gln8 prevents asparagine rearrangement, Ala15 enhances bioactivity, and Leu27 prevents methionine oxidation. MiPeptidos offers CJC 1295 (without DAC) in 3 sizes with 99.7% verified purity and full analytical documentation.
- Physiological GH release
- Better deep sleep
- Faster workout recovery
- Leaner body composition
In weeks 1-2, studies report noticeably better sleep within the first few days as natural growth hormone pulses are restored. By weeks 3-6, research suggests faster recovery from training, improved skin quality, and early body composition shifts. Weeks 7-12 bring visible lean mass gains and fat reduction with sustained energy throughout the day.
$16.80/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Natural GH Pulsatility.
12-week GHRH protocol preserving your body's natural growth hormone rhythm
CJC-1295 without DAC, also known as Modified GRF (1-29) or Mod GRF 1-29, is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions (Ala2, Ala8, Ala15, Ala27 → D-Ala2, Gln8, Ala15, Leu27) for enhanced stability against enzymatic degradation.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. William Seeds
Founder, SSRP Institute
40+ years in cellular and molecular medicine. Author of 'Peptide Protocols: Volume 1'.
Mod GRF 1-29 is my preferred GHRH analog for most patients because it preserves the natural pulsatile GH pattern. Combined with ipamorelin, it produces the most physiological GH release available.
100 mcg subcutaneous 2–3 times daily, ideally combined with 200–300 mcg ipamorelin at each dose. Dose before bed, upon waking, and optionally post-workout.
Fuente: Peptide Protocols: Volume 1 (ISBN: 978-0578624358)
Dr. Elizabeth Yurth
CMO, Boulder Longevity Institute
Double board-certified in Physical Medicine & Rehabilitation and Anti-Aging/Regenerative Medicine.
I prefer the non-DAC variant because you get pulsatile GH release just like your body naturally produces. The pulse is what matters — continuous GH elevation is not physiological.
100–200 mcg subcutaneous at bedtime, combined with ipamorelin. Always on an empty stomach. The GH pulse peaks within 30 minutes and returns to baseline within 2 hours.
Fuente: Boulder Longevity Institute Clinical Protocols
Dr. Andrew Huberman
Professor of Neurobiology, Stanford University
Ph.D. in Neuroscience. Host of Huberman Lab.
If you're going to use a GHRH analog, the non-DAC version makes more physiological sense. It creates a GH pulse rather than a sustained elevation, which better mimics what your pituitary does naturally during deep sleep.
Bedtime dosing to amplify the natural nocturnal GH pulse. Combine with ipamorelin for dual-pathway activation. Always fasted — insulin blunts GH release.
Fuente: Huberman Lab Podcast: Peptide Therapeutics Discussion (2024)
Dr. Richard Walker
Professor of Endocrinology, University of South Florida
Neuroendocrinologist specializing in GH axis physiology and aging. Published extensively on GHRH analogs and age-related GH decline.
GHRH analogs like Mod GRF 1-29 restore the amplitude of GH pulses that naturally diminish with aging, without overriding the somatostatin-mediated feedback that prevents continuous secretion.
100 mcg per injection, 1–3 times daily. The short half-life ensures GH returns to baseline between doses, maintaining the pulsatile pattern critical for receptor sensitivity.
Fuente: Walker et al. (2006) Am J Physiol Endocrinol Metab
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Start with bedtime dose only. Add morning fasted dose in week 2 if well tolerated. Always administer on empty stomach — insulin suppresses GH release.
Combine with ipamorelin (200–300 mcg) at each dose for synergistic GHRH+GHRP activation. Post-workout dose optional but recommended on training days.
Return to single bedtime dose before cycling off. Take 4 weeks off between cycles. Short half-life allows rapid clearance.
Add 2.5 mL bacteriostatic water to 5 mg vial = 2,000 mcg/mL. 100 mcg = 5 units on insulin syringe.
Standard: 8–12 weeks on, 4 weeks off. Some practitioners run 5 days on / 2 days off. Shorter cycles (6–8 weeks) acceptable for beginners.
Lyophilized: -20°C for 24+ months. Reconstituted: 2–8°C, use within 28 days. More stable than native GHRH due to amino acid substitutions.
Must be administered fasted — insulin suppresses GH release. Wait 30+ minutes post-injection before eating. Combine with GHRP at same injection for synergistic effect (can mix in same syringe).
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
GH Pulse Restoration
- GH pulse detectable within 15–30 minutes of injection
- Improved sleep quality and depth within the first week
- Morning energy and recovery improvements begin
- No water retention or joint effects at these doses
- IGF-1 begins to rise with consistent bedtime dosing
Base de investigación: Iovino et al. (2012) J Endocrinol Invest; pharmacokinetic profiles of Mod GRF 1-29
Recovery & Composition Changes Begin
- Measurably faster recovery from exercise
- IGF-1 elevated 20–50% above baseline
- Improved skin quality, hydration, and healing
- Early body composition changes — improved muscle fullness
- Enhanced deep sleep EEG patterns
Base de investigación: GHRH analog literature; Van Cauter et al. (2000) JAMA
Peak Benefits & Recomposition
- Significant body composition improvements visible
- Lean mass gains and subcutaneous fat reduction measurable
- Exercise capacity and recovery at their best
- Hair, skin, and nail quality improvements notable
- Sustained energy and vitality throughout the day
Base de investigación: Clinical peptide therapy observations; GHRH analog response timelines
Taper & Cycle Off
- GH levels return to baseline rapidly after discontinuation (short half-life)
- Body composition gains maintained with continued training and nutrition
- No withdrawal effects or rebound
- Pituitary sensitivity maintained due to pulsatile delivery pattern
Base de investigación: Pharmacokinetic elimination data; GHRH receptor physiology
Mecanismo de Acción
3 vías biológicas distintas a través de las cuales opera este péptido.
GHRH Receptor Agonism (Pulsatile)
Mod GRF 1-29 binds GHRH receptors on pituitary somatotrophs, triggering cAMP/PKA signaling for GH synthesis and release in a discrete pulse lasting 30–60 minutes.
- Produces a GH pulse peaking at 15–30 minutes post-injection
- GH returns to baseline within 2 hours — preserving natural pulsatility
- Somatostatin feedback remains intact, preventing continuous secretion
Frohman et al. (1989) PMID: 2507221
GHRH-GHRP Synergy
GHRH and GHRP activate separate receptor systems (GHRH-R and GHSR) that converge intracellularly to produce synergistic GH release 3–5 times greater than either pathway alone.
- GHRH activates cAMP/PKA; GHRP activates PLC/IP3/PKC
- Separate second messenger systems converge on GH gene transcription
- 3–5 fold amplification over single-pathway stimulation
Bowers et al. (2004) PMID: 15126525
Nocturnal GH Restoration
Bedtime dosing amplifies the natural nocturnal GH surge that occurs during slow-wave sleep, restoring age-related declines in overnight GH secretion.
- 70% of daily GH secretion normally occurs during sleep
- Slow-wave sleep and GH pulses decline in parallel with aging
- Bedtime GHRH restores nocturnal GH output to youthful levels
Van Cauter et al. (2000) JAMA; PMID: 10944644
Investigación Publicada
5 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Structure-activity relationships of GHRH(1-29)-NH2 analogues: replacement of Tyr1
Ling N, Esch F, Bohlen P, Brazeau P, Wehrenberg WB, Guillemin R — Biochemical and Biophysical Research Communications (1984)
Hallazgo Clave: Established that the first 29 amino acids of GHRH retain full biological activity for GH release. The minimal active sequence for GHRH receptor activation.
Growth hormone-releasing hormone (GHRH): discovery, chemistry, and potential therapeutic applications
Frohman LA, Downs TR, Heimer EP, Felix AM — Frontiers in Neuroendocrinology (1989)
Hallazgo Clave: Amino acid substitutions at positions 2, 8, 15, and 27 of GHRH(1-29) dramatically improve resistance to enzymatic degradation (DPP-IV) while maintaining full receptor binding affinity.
Growth hormone releasing peptides synergistically stimulate GH release with GHRH in normal volunteers
Bowers CY, Granda R, Mohan S, et al. — Journal of Clinical Endocrinology & Metabolism (2004)
Hallazgo Clave: Combined GHRH + GHRP administration produced GH release 3–5 times greater than either alone. Confirmed the synergistic dual-pathway amplification principle.
Effect of low-dose recombinant human GHRH on GH secretion in healthy elderly men
Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR — Journal of Clinical Endocrinology & Metabolism (1992)
Hallazgo Clave: Low-dose GHRH (1 mcg/kg) administered before bed for 14 nights increased nocturnal GH secretion 2-fold in healthy elderly men without tachyphylaxis.
Pulsatile GHRH increases GH pulsatility and mean GH concentration in growth hormone deficient adults
Jaffe CA, Turgeon DK, Lown K, et al. — American Journal of Physiology (1999)
Hallazgo Clave: Pulsatile GHRH administration (every 3 hours) restored normal GH pulsatile secretion in GH-deficient adults, increasing both mean GH and pulse amplitude.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar CJC 1295 (without DAC) con estos péptidos para mecanismos complementarios.
The most widely used and well-studied GH secretagogue combination. CJC-1295 (GHRH pathway) + Ipamorelin (GHRP pathway) produces synergistic GH pulses far beyond either alone.
Gold standard for practitioners — clean GH elevation with preserved pulsatility and minimal side effects. Available as a pre-mixed combo vial.
GHRP-6 provides strong ghrelin receptor activation with appetite stimulation — useful for recovery and mass-gaining protocols.
Maximized GH release with enhanced appetite — ideal for recovery from injury, surgery, or caloric deficit.
Hexarelin is the strongest GHRP available. Paired with CJC-1295, it produces the highest GH pulse amplitude of any secretagogue combination.
Maximum GH pulse amplitude. Reserve for advanced researchers who have plateaued on CJC/Ipamorelin combinations.
BPC-157 upregulates GH receptors up to 7-fold, amplifying the tissue-level effects of CJC-1295-induced GH pulses.
Amplified tissue repair: GH elevation plus receptor upregulation equals dramatically enhanced healing at injury sites.
Especificaciones
Cómo Funciona CJC 1295 (without DAC)
Mod GRF 1-29 is a modified 29-amino acid fragment of GHRH with four amino acid substitutions that prevent enzymatic degradation: D-Ala2 prevents DPP-IV cleavage, Gln8 prevents asparagine rearrangement, Ala15 enhances bioactivity, and Leu27 prevents methionine oxidation. Without the DAC moiety, it produces more physiologic pulsatile GH release patterns, stimulating somatotrophs through GHRH receptors with a much shorter duration of action.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 | Ahorro |
|---|---|---|---|
2mgOferta | $23.95$40.00 | $203.57 | 40% descuento |
5mgOferta | $47.95$60.00 | $407.57 | 20% descuento |
10mgMejor Valor | $80.00 | $680.00 | — |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Not FDA-approved for human use
Mod GRF 1-29 is a research peptide. It is not an approved pharmaceutical. All information is for research and educational purposes.
Contraindicated with active cancer or tumors
GH elevation from any secretagogue can promote cell proliferation. Do not use with active malignancy or history of GH-dependent tumors.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
HGH
Estudiado para la restauración de vías de recuperación relacionadas con la edad
Up to 37% OffHGH Fragment 176-191
Estudiado para lipólisis dirigida sin efectos de crecimiento
CJC1295 with DAC
Estudiado para soporte sostenido de GH con dosificación semanal
CJC 1295 5mg + IPA 5mg
El péptido estándar de oro estudiado para la optimización de GH